2 results
Approved WMOCompleted
To assess the effect of switching CML patients, who have been treated with imatinib *2 years and who have stable detectable molecular residual disease above 0.01% (IS), to the combination of Nilotinib and PegIFN, in terms of the proportion of…
Approved WMORecruiting
Primary Objective There are two co-primary objectives; one regarding each tibial component configuration, fixed bearing (FB) and rotating platform (RP): 1) Evaluate change from preoperative baseline to the 2 yr timepoint in patient reported…